Introduction
The class III receptor tyrosine kinase (RTK) family consists of FLT3, KIT, FMS, and the two PDGF receptors. The members of this receptor family play important roles in cell growth, survival and development in hematopoiesis. The class III receptors share structural characteristics including five extracellular immunoglobulin-like domains, a single transmembrane domain and a kinase domain interrupted by a kinase insert. 1, 2 FLT3 is preferentially expressed on hematopoietic stem/progenitor cells as well as dendritic cell precursors. 3, 4 Binding of FLT3 ligand (FL) to FLT3 results in receptor dimerization, activation of the intrinsic tyrosine kinase activity and receptor autophosphorylation. 5 FLT3 activates cytoplasmic signaling mediators through direct phosphorylation or association, including PLC-␥, the p85 subunit of P13 kinase, VAV, CBL, SHP2, SHIP, STAT 5A, STAT 5B and ras GTPase-activating protein. [6] [7] [8] [9] FLT3 signaling is important in hematopoietic stem cells, development of B cell progenitors, NK cells and dendritic cells. 3, [10] [11] [12] In addition to a role in normal hematopoiesis, recent studies have established an important role for FLT3 in leukemia. Expression of both FLT3 and FL has been found in many leukemia-derived cell lines, and FLT3 is aberrantly expressed in most primary acute leukemia samples. [13] [14] [15] [16] [17] Thus, the possibility of constitutive activation of FLT3 in these cells through autocrine, paracrine or intracrine mechanisms exists. FLT3 auto-activation could provide signaling for cell proliferation, as well as a block in differentiation and apoptosis, all characteristics of leukemogenesis.
Recent studies from our laboratory and others have provided further evidence for a possible pathogenic role for FLT3 in leukemogenesis. 9, 18 Constitutively activated FLT3 can induce cellular transformation in transfected Ba/F3 and 32D cells and the development of leukemia in mice inoculated with these cells. Interestingly, over-expression of wild-type FLT3 in Ba/F3 cells also results in leukemia when injected into syngeneic mice, probably through activation by endogenous FL. 9 Overexpression of FL also increases the propensity of mice to develop leukemia.
Besides over-expression of wild-type FLT3 in leukemia, somatic mutations consisting of in-frame internal tandem duplications (ITDs) of the juxtamembrane region of the FLT3 gene have been reported in 17-34% of AML patients, 5% of myelodysplastic patients (MDS) and a small number of ALL patients. [19] [20] [21] [22] AML patients with the ITD mutations have an especially poor prognosis. [23] [24] [25] [26] [27] [28] The recent finding of in-frame mutations of D835 within the activating loop of FLT3 in 7% of AML, 3.4% of MDS and 2.8% of ALL cases, provides further evidence that FLT3 mutations probably play a role in hematologic malignancies. 21, 29 Both types of mutations appear to constitutively activate the tyrosine kinase activity of FLT3 with resultant downstream activation of proteins, including the ERK and JAK-STAT pathways. 9, 18, 30 The cumulative data supporting the involvement of activated FLT3 in leukemia prompted us to search for an inhibitor of its tyrosine kinase activity for use as a possible therapeutic intervention. Selective inhibition of the kinase activity of members of the type III RTK family has been previously reported for several low molecular weight compounds from the class of tyrphostins. One such compound, AG1296, selectively blocks the kinase activities of both the PDGF receptor and KIT, but has no effect on the EGF receptor or the vascular endothelial growth factor receptor, KDR. 31, 32 Our recent study has shown that AG1296 is also a potent inhibitor of FLT3 activated by fusion with TEL, with an IC 50 in the micromolar range. 33 In addition, we recently demonstrated that another tyrphostin, AG1295, was selectively cytotoxic to primary leukemic blasts from AML patients harboring a FLT3/ITD mutation. 34 In this study, we examined the downstream signaling of FLT3/ITDs isolated from AML patient samples in a factordependent cell line. The responses of these FLT3/ITD-expressing cell lines to the FLT3 inhibitor AG1296 were then correlated with changes in signal transduction, cell proliferation and death.
Materials and methods

Antibodies and reagents
Drs Alexander Levitzki and Aviv Gazit (Hebrew University, Jerusalem, Israel) provided the tyrphostin AG1296 used in this study. The synthetic methods and analytical data on the tyrphostins have been described previously. 31, 32 For in vitro and cellular assays, a stock solution of AG1296 at a concentration of 10 mmol/l was prepared in dimethylsulphoxide (DMSO) and stored at −20°C.
Recombinant human FL and murine IL-3 were purchased from Peprotech (Rocky Hill, NJ, USA). Polyclonal antibodies against FLT3 (S-18), STAT 5A/B, VAV, CBL, SHP2, p-ERK and ERK were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Mouse monoclonal antibody against phosphotyrosine (4G10) and recombinant protein A-agarose was purchased from Upstate Biotechnology (Lake Placid, NY, USA). Horseradish peroxidase-conjugated secondary antibodies and enhanced chemiluminescence detection system were from Amersham (ECL, Arlington Heights, IL, USA).
AML patient samples
Bone marrow samples from patients with AML were obtained as part of an institutional review board-approved protocol and prepared as described. 34 Samples were screened for the presence of FLT3/ITD mutations as described below.
RT-PCR cloning of FLT3/ITDs from AML patient samples
Total RNA was extracted from the AML patient samples by use of the RNeasy kit (Qiagen, Valencia, CA, USA). RT-PCR was performed using the one-step RT-PCR kit (GIBCOaq1) using forward primer: 5Ј-CAATTG (Mun1)-TGTCGAGCAG-TACTCTAAACA-3Ј and reverse primer: 5Ј-GCATGC (Sph1)-ATCCTAGTACCTTCCCAAACTC-3Ј 3, 19 at 94°C, 55°C and 72°C (1 min each) for 35 cycles with a final extension of 10 min at 72°C. The PCR products were resolved on 2.5% agarose gels (GIBCO) with ethidium bromide staining. Actin was also amplified as a control using primers 5Ј-GCTCGTCGTCGACAACGGCTC-3Ј and 5Ј-CAAACATGATCT GGGTCATCTTCTC-3Ј. FLT3/ITD DNA fragments were detected as bands migrating above the wild-type FLT3 fragment (expected size, 365 bp). These higher molecular weight DNA fragments were isolated and sequenced. FLT3/ITD fragments were then digested with Mun1 and SphI and ligated to the Mun1 and SphI digested full-length FLT3 cDNA to replace the same region in the wild-type FLT3 cDNA. The cDNA was subcloned into the pCIneo expression vector (Promega, Madison, WI, USA) and used for transfection of factor-dependent cell lines.
Cell lines and transfection
The murine IL-3-dependent pro-B cell line, Ba/F3, was maintained in RPMI 1640 medium (GIBCO, Rockville, MD, USA) supplemented with 10% fetal bovine serum (FBS, Gemini BioProducts, Calabasas, CA, USA) and 1 ng/ml IL-3. Ba/F3 cells were transfected with plasmid DNA by electroporation at 300 mV/960 F (Bio-Rad, Richmond, CA, USA). Transfected cells were cultured in IL-3-containing medium for 48 h and then selected in 1 mg/ml G418 (GIBCO) for a period of 2 weeks. The ability of the cells to survive in the absence of IL-3 was determined by trypan blue exclusion after plating aliquots of the washed cells in 96-well plates. Transfected cell lines were then subcloned by limiting dilution.
Immunoprecipitation and immunoblot analysis
To determine the phosphorylation status of FLT3/ITDs and to evaluate the ability of AG1296 to inhibit the phosphorylation of FLT3 and its downstream signaling effectors, AG1296 in DMSO, or DMSO alone, was added to cell lines or primary AML samples in culture at the indicated concentrations for 4 h at 37°C (final DMSO concentrations were kept constant at 0.5%) in the presence or absence of FL and/or IL-3 as indicated. Cells were washed twice with ice-cold phosphate buffered saline (PBS) and lysed for 30 min in ice-cold NP-40 lysis buffer (20 mmol/l Tris-HCl, pH 7.4, 150 mmol/l NaCl, 100 mmol/L NaF (Sigma, St Louis, MD, USA), 10% glycerol, 1% NP-40 and 10 mmol/l EDTA) containing protease and phosphatase inhibitors (2 mmol/l sodium orthovanadate, 50 g/ml antipain, 5 g/ml aprotinin, 1 g/ml leupeptin and 10 g/ml phenylmethylsulfonyl fluoride; Sigma).
Clarified lysates (500 g) were immunoprecipitated by incubation for 16 h at 4°C with antibodies against either FLT3, STAT 5A/B, VAV, CBL or SHP2 followed by subsequent incubation with recombinant protein A-agarose for 3 h at 4°C. Immunocomplexes were washed four times in TBST (10 mmol/l Tris-HCl, pH 7.4, 100 mmol/l NaCl, 0.1% Tween-20), twice in TBS (10 mmol/l Tris-HCl, pH 7.4, 100 mmol/l NaCl), boiled in sample buffer and resolved by SDS-polyacrylamide gel electrophoresis (PAGE). Total protein lysates (50 g each lane) were also resolved by PAGE for the analysis of p-ERK. For immunoblotting, proteins were transferred to Immobilon membranes (Millipore, Bedford, MA, USA), blocked in 5% bovine serum albumin (BSA, Sigma) in TBST for 3 h and probed for 2 h at room temperature with specific primary antibodies. Blots were washed extensively in TBST and incubated with horseradish peroxidase-conjugated secondary antibody (1:2500 dilution) and substrate. The chemiluminescent blots were then exposed to film. In some cases, blots were stripped of antibody by washing in buffer containing 200 mmol/l glycine (pH 2.5) and 0.05% Tween-20 for 2 h at 80°C for successive probing with different antibodies.
Cell proliferation assay
To evaluate the cytotoxic effects of AG1296, an MTT-based assay system (Boehringer Mannheim, Indianapolis, IN, USA) was used. Ba/F3 or Ba/F3-derived cells were plated in triplicate at 1 × 10 5 cells per well in 96-well plates with or without IL-3 supplement and in the presence of various concentrations of AG1296 or AG1879. Primary AML samples were plated at 2 × 10 5 per well in triplicate. Inhibitor-free controls contain the same amount of DMSO (final concentration 0.5%) as in the experimental groups. Cells were incubated at 37°C for 3 days to determine the anti-proliferative or cytotoxic effects of the inhibitors. At daily intervals, 10 l of MTT [3-(4.5-dimethylthiazol-2-yl)-2.5-diphenyltetrazolium bromide] at a final concentration of 0.5 mg/ml was added to each well for 4 h. The resultant formazan crystals were dissolved with the addition of 100 l solubilization solution containing 10% SDS in 0.01 mmol/l HCl, incubated overnight, and quantitated using a microplate reader (Molecular Devices, Sunnyvale, CA, USA) at 562 nm. The absorbances (optical density, OD) were corrected for blank readings. In this assay, MTT is reduced to colored formazan crystals in proportion to the number of viable cells. The concentration of inhibitor corresponding to a 50% inhibition of cell proliferation (IC 50 ) was determined by analyzing the resultant graphs.
Apoptosis analysis
Phycoerythrin (PE)-conjugated annexin V (annexin V-PE, Pharmingen, San Diego, CA, USA) binding to phosphatidylserine was used to evaluate the induction of apoptosis by AG1296. Cells were plated at 2.5 × 10 5 per well in 24-well plates in the presence or absence of increasing concentrations of AG1296 and with or without the addition of IL-3. DMSO was kept constant at 0.5% in both the controls and for all levels of inhibitor-treated cells. At daily intervals, cells were harvested, washed and resuspended in binding buffer. Annexin V-PE and the vital stain 7-amino-actinomycin D (7-AAD, Pharmingen) were added to the cell suspension followed by incubation at room temperature for 15 min. Flow cytometry was performed immediately after staining on a FACSort flow cytometer (Becton Dickinson, Mountain View, CA, USA). Analysis was performed using the Cellquest software package (Becton Dickinson).
Results
Cloning and expression of FLT3/ITD mutant receptors
To isolate FLT3/ITDs for this study, total RNA extracted from 10 patients diagnosed with AML was amplified with specific primers for FLT3 by RT-PCR. Four FLT3/ITDs ranging from 18 bp (6 aa) to 81 bp (27 aa) duplications were identified in the screen. The 18 bp (ITD 1) and 81 bp (ITD 2) duplicated fragments were isolated and used in this study as representative samples because of differences in their location and lengths of the duplication (Figure 1 ). Similar results were obtained from other ITDs.
Following cloning, expression vectors containing the FLT3/ITDs were introduced into the IL-3-dependent murine Ba/F3 cells through electroporation. To determine whether the transfected cells express activated FLT3/ITD, protein lysates prepared from selected clones grown in the presence or absence of FL were immunoprecipitated with an antibody specific for FLT3, followed by PAGE and immunoblotting with an anti-phosphotyrosine antibody (4G10). Results show that both FLT3/ITD proteins were expressed (Figure 2 , lanes 1 and 9, lower panels) in contrast to the parental Ba/F3 cells, which lack FLT3 expression (data not shown). These FLT3 receptor mutants were constitutively phosphorylated in the absence of added FL in Ba/F3 cells (Figure 2, lanes 1 and 9, upper panels) . Addition of FL to the cultures before cell lysis resulted in little
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Figure 1
Schematic illustration of the FLT3/ITDs isolated from AML patient samples. The predicted amino acid sequence of human wild-type FLT3 spanning from 584 to 614 is shown. The ITD sequences are underlined. Arrows indicate inserted amino acids detected in the ITDs. ECD, extracellular domain, PM, plasma membrane; JM, juxtamembrane domain; TK, tyrosine kinase domain.
Figure 2
Constitutive tyrosine phosphorylation of FLT3/ITDs in transfected Ba/F3 cells and inhibition by AG1296. FLT3/ITD expressing cell lines were incubated at 37°C in growth medium containing DMSO alone (lanes 1 and 9) or increasing concentrations of AG1296 for 4 h in the presence or absence of FL (100 ng/ml) and/or IL-3 (1 ng/ml) for 15 min. Cells were lysed and equal amounts of lysates were immunoprecipitated (IP) with antibody of FLT3. Immunoprecipitates were resolved by PAGE. Immunoblot (IB) analyses were carried out with an anti-phosphotyrosine (4G10) antibody (upper panel) followed by blotting with anti-FLT3 antibody (lower panel). Lanes 1-8, FLT3/ITD #1; lanes 9-16, FLT3/ITD #2.
further activation of the mutant receptors, suggesting that both FLT3/ITDs were close to maximally activated in the expressing cells (Figure 2, lanes 5 and 13, upper panels) .
Inhibition of FLT3/ITD autophosphorylation by AG1296 in transfected Ba/F3 cells
AG 1296 potently inhibits ligand-dependent wild-type PDGFR, KIT and FLT3 activation in cells expressing these receptors. 33, 35 Thus, we sought to determine whether AG1296 also inhibits FLT3/ITD mutant activation in transfected Ba/F3 cells. Exposure of cells to increasing concentrations of AG1296 for 4 h before cell lysate preparation potently inhibited the auto-phosphorylation of both FLT3/ITDs in a concentration-dependent manner, with an IC 50 of approximately 1 M and a complete inhibition at 10 M (Figure 2,  lanes 1-8 and 9-16, upper panels) . Expression of FLT3/ITD protein was not significantly affected by the presence of the Leukemia inhibitor ( Figure 2, lanes 1-8 and 9-16 , lower panels). These data suggest that AG1296 is an inhibitor of FLT3/ITD kinase activity in cells expressing these mutant receptors.
As Figure 2 shows, the FLT3/ITD receptors are phosphorylated in the absence of added ligand. This finding does not preclude the possibility, however, that ligand binding to these receptors could further stabilize the active conformation of the receptor and in turn influence the binding of AG1296. To determine whether addition of FL to the cultures prior to cell lysis would influence the effect of Ag1296-mediated inhibition, FL was added to the cell cultures prior to addition of inhibitor. As shown in Figure 2 , FL addition increased the IC 50 of AG1296 for FLT3/ITD inhibition (Figure 2, lanes 1-4 vs 5-8 , and 9-12 vs 13-16 upper panels).
AG1296 inhibits proliferation of FLT3/ITD-transformed Ba/F3 cells
To determine whether inhibition of constitutive activity of FLT3/ITDs by AG1296 would translate into growth inhibition, Ba/F3 cells expressing FLT3/ITDs were first examined for IL-3-independent growth by MTT-based cell proliferation assays. Both FLT3/ITD expressing cell lines proliferated without either FL or IL-3 addition at the same rate as their parental counterparts when supplemented with IL-3 (data not shown). MTT assays were used to determine the effect of AG1296 and the SRC inhibitor AG1879 on the growth of these FLT3/ITD expressing cells. Cells were treated with increasing concentrations of each inhibitor and cell proliferation assays were performed daily. AG1879 had little effect on growth of both FLT3/ITD expressing cell lines (Figure 3a and b) . In contrast, AG1296 inhibited the proliferation of cells expressing either form of FLT3/ITD in a dose-dependent fashion with IC 50 values of 0.5-0.8 M (Figure 3a and b) . Neither drug inhibited the proliferation of Ba/F3 parental cells, indicating that they are not cytotoxic to Ba/F3 cells (data not shown).
As shown earlier, addition of exogenous FL partially overcame the inhibition of FLT3 autophosphorylation at low levels of AG1296 (Figure 2 ). This finding led us to predict that the dose-response curve for AG1296 would shift to the right (ie more resistant). This, in fact, was observed (Figure 3a and b) . Addition of IL-3 rescued the growth AG1296-treated cells (Figure 3a and b) . Taken together, these data indicate that AG1296 exerts an anti-proliferative effect on Ba/F3 cells transformed by FLT3/ITDs through direct inhibition of FLT3 while leaving the IL-3 signaling pathway intact, an additional measure of the relative selectivity of AG1296 for FLT3.
AG1296 induces apoptosis in FLT3/ITD expressing cells
To determine whether AG1296 induces cell death, parental Ba/F3 and FLT3/ITD-transformed Ba/F3 cell lines were exposed to increasing concentrations of AG1296. Apoptosis was assayed by binding of Annexin V-PE following 24, 48 and 72 h of incubation with inhibitor.
As demonstrated in Figure 4 , there was a background of 7-26% apoptosis in the inhibitor-free cultures among the cell lines examined. When the parental Ba/F3 cell line was incubated with increasing concentrations of AG1296, it did not undergo any increase in apoptosis, even at the highest concentration of 10 M used (Figure 4a, 48 h data is shown) . In contrast, cells expressing FLT3/ITD No. 1 showed a dose- 
Inhibition of FLT3-mediated map kinase activation pathway by AG1296
Activation of RAS pathways leading to proliferation and survival are important parts of normal and mutant FLT3 signaling. 30 Among the downstream components in the course of flt3 signaling, VAV proteins are SH2-SH3 containing proteins which become rapidly and transiently phosphorylated on tyrosine residues. This leads to the activation of guanine nucleotide exchange activity, thus activating the RAS-related RHO family and ultimately leading to map kinase activation. 36 To examine the effects of AG1296 on VAV phosphorylation, total cell lysates from FLT3/ITD expressing cell lines were immunoprecipitated with anti-VAV antibody and immunoblotted with 4G10 and followed by anti-VAV antibodies. VAV was constitutively phosphorylated in both cell lines ( Figure 5 , lanes 1 and 9). AG1296 at doses of 5 M or higher reduced the phosphorylation of VAV in both cell lines ( Figure 5 , lanes 1-4 and 9-12). Addition of FL (lanes 5-8 and 13-16) did not alter the profile of inhibition by AG1296. There was no significant change in the expression of VAV protein in cells treated with AG1296 (lower panels of VAV blots).
The effects of AG1296 on MAP kinase phosphorylation were examined next. An antibody that recognizes tyrosinephosphorylated forms of MAP kinases was used to immunoblot cell lysates prepared in the presence or absence of AG1296 treatment. Both FLT3/ITD expressing cell lines showed a significant amount of MAP kinase auto-phosphorylation without FL, and this was true for both pp42 erk2 and pp44 erk1 ( Figure 5, lanes 1 and 9) . AG1296 significantly inhibited the phosphorylation of pp42 erk2 with an IC 50 of less than 5 M in both cell lines ( Figure 5, lanes 1-4 and 9-12 ).
Figure 5
Effect of FLT3 inhibition by AG1296 on the phosphorylation of proteins in the RAS/Rac1/MAP kinase activation pathways. Cell lines expressing FLT3/ITDs were treated with increasing concentrations of AG1296 for 4 h with or without 100 ng/ml FL and/or 1 ng/ml IL-3. Cell lysates were prepared and subject to immunoprecipitation (IP) with an anti-VAV antibody followed by PAGE and blotting. The resulting membranes were immunoblotted (IB) consecutively with an anti-phosphotyrosine (4G10) antibody followed by an anti-VAV antibody. To measure the effects of AG1296 on MAP kinase phosphorylation in leukemic cell lines, total cell lysates were extracted, resolved by PAGE and immunoblotted with a specific antibody that recognizes specifically phosphorylated MAP kinases (p-p42/ERK2 and p-p44/ERK1). The membranes were then stripped and re-probed with an anti-MAP kinase antibody for total ERK1 and ERK2 expression. Data are representative of one of three independent experiments. Lanes 1-8, FLT3/ITD #1; lanes 9-16, FLT3/ITD #2.
Addition of FL to the cultures did not significantly affect the AG1296-mediated inhibition in either cell line ( Figure 5 ). MAP kinase expression was not altered by treatment with AG1296 ( Figure 5 , lower panels of ERK blots).
Inhibition of FLT3-mediated phosphorylation of STAT 5 protein by AG1296
Activation of many growth factor/cytokine receptors induces tyrosine phosphorylation of proteins in the JAK-STAT signal transduction pathway. 37, 38 Phosphorylation of STAT 5 is a frequent finding in leukemia and has been implicated in leukemogenesis, perhaps contributing to a block in differentiation. Previous studies from our group and others showed that constitutively activated FLT3 induced phosphorylation of both STAT 5A and STAT 5B. 9, 18, 30 To determine the phosphorylation status of STAT 5 proteins in FLT3/ITD expressing Ba/F3 cells, cell lysates from FLT3/ITD cell lines were subject to immunoprecipitation with antibody specific for both STAT 5A and STAT 5B and immunoblotted with 4G10, followed by anti-STAT 5 A/B antibody. Both forms of STAT 5 proteins were constitutively phosphorylated in FLT3/ITD cells ( Figure 6 , lanes 1 and 9; STAT 5A: upper band, STAT 5B: lower band). AG1296 inhibited STAT 5A and 5B phosphorylation in a dose-dependent fashion, with an IC 50 of approximately 1 M and complete inhibition at 5 M ( Figure  6, lanes 1-4 and 9-12 ). Re-probing the same blots with an anti-STAT5 A/B antibody showed that the decreases in phosphorylation were not due to changes in the expression of STAT 5 A/B proteins (lower panel). IL-3, which is known to activate both forms of STAT 5 phosphorylation, reversed AG1296-mediated inhibition of STAT 5 phosphorylation ( Figure 6, lanes 17-24) . This demonstrates that the inhibition by AG1296 is not a result of direct inhibition of STAT 5 phosphorylation but is a downstream consequence of FLT3/ITD inhibition.
AG1296 inhibits FLT3-mediated phosphorylation of proteins involved in down-regulation of kinasemediated signaling cascades
CBL is a 120 kDa protein originally isolated as the cellular homologue of the product of the transforming oncogene v-cbl of the Cas NS-1 retrovirus. [39] [40] [41] It has been suggested to function as a down-regulator of proteins involved in tyrosine kinase activated signal transduction by targeting these proteins for ubiquitin-mediated degradation. CBL is a target of tyrosine phosphorylation following cytokine stimulation by IL-3 and FL. 42, 43 Immunoprecipitation and immunoblotting showed that both FLT3/ITD cell lines expressed constitutively phosphorylated CBL (Figure 7, lanes 1 and 9) . Phosphorylation of CBL was inhibited by AG1296 in both cell lines, with an IC 50 of approximately 1 M and complete inhibition by 5 M (lanes 1-4 and 9-12) . Adding FL to the cultures increased the IC 50 of AG1296 to 5 M (lanes 5-8 and 13-16). There was no modulation of CBL protein expression by AG1296 (lower panels).
SHP2 is a tyrosine phosphatase, which acts as an attenuator of signal transduction in response to the activation of several receptors by removing phosphate from tyrosine residues on target proteins. 44, 45 Previous studies have shown FL induces FLT3 phosphorylation of SHP2 and its association with adapter proteins such as GRB2 and P13K. 46 In both FLT3/ITD
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Figure 6
Inhibition of FLT3-mediated phosphorylation of CBL and SHP2 by AG1296. Cells transformed by both FLT3/ITDs were treated with the indicated concentrations of AG1296 for 4 h in the presence or absence of 100 ng/ml FL and/or 1 ng/ml IL-3 for 15 min. Equal amounts of cell lysates were subject to immunoprecipitation (IP) with an anti-CBL or anti-SHP2 antibody followed by PAGE and blotting. The resulting membranes were analyzed by immunoblotting (IB) using an anti-phosphotyrosine (4G10) antibody. The membranes were then stripped and reprobed with an antibody for CBL or SHP2. Data are representative of one of three independent immunoblot analyses. Lanes 1-8, FLT3/ITD #1; lanes 9-16, FLT3/ITD #2.
Figure 7
Effects of FLT3 inhibition by AG1296 on tyrosine phosphorylation of STAT5. Cell lines expressing both forms of FLT3/ITDs were incubated in the presence of the indicated concentrations of AG1296 for 4 h with the addition of FL and/or IL-3 for 15 min prior to cell lysis. Cell lysates were prepared and equal amounts of cell lysates were used for immunoprecipitation (IP) with an anti-STAT 5A/B antibody (recognizes both 5A and 5B) followed by PAGE and blotting. The resulting membranes were immunoblotted (IB) with an anti-phosphotyrosine (4G10) antibody. The membranes were then stripped and re-probed with an antibody for STAT5. Data are representative of one of four independent experiments. Lanes 1-8 and 17-20, FLT3/ITD #1; lanes 9-16 and 21-24, FLT3/ITD #2.
expressing cell lines, SHP2 was constitutively phosphorylated (Figure 7 , lanes 1 and 9, upper panels of SHP2 blots). Treatment with AG1296 caused a significant inhibition of SHP2 phosphorylation at 5 and 10 in both cell lines (Figure 7 , lanes 1-4 and 9-12). SHP2 protein expression was not altered by treatment with AG1296 (lower panels). FL addition did not significantly shift the dose-response curve for inhibition of SHP2 phosphorylation by AG1296 (Figure 7 , lanes 5-8 and 13-16).
AG1296 inhibits FLT3 phosphorylation and is cytotoxic to AML blasts harboring FLT3/ITD mutations
One goal of these studies is to validate the potential of FLT3 as a therapeutic target for a disease such as AML. An important step in this process is to confirm that the cytotoxic effects of AG1296 we have observed in the cell lines are also seen in primary blast samples from AML patients, particularly Leukemia those harboring FLT3/ITD mutations. Three separate samples of bone marrow mononuclear cells from AML patients harboring FLT3/ITD mutations were treated with AG1296. As shown in Figure 8 , FLT3 autophosphorylation was completely inhibited by 10 M AG1296, while the cells displayed doseresponsive cytotoxicity as determined from the MTT assay.
Discussion
Mutations in FLT3, which constitutively activate its tyrosine kinase activity, are the most frequent genetic alteration in AML. 21, 22, 24, 25, 28, 29, 47, 48 The mutant receptor appears to play an important role in these cells because multiple studies show that AML patients expressing mutant FLT3 have a worse prognosis. Therefore, the addition of drugs that would inhibit the kinase activity of FLT3 might improve the cure rate for this disease.
Our previous studies identified a compound from the tyr-
Figure 8
Primary leukemia samples treated with AG1296. Three different frozen samples of bone marrow mononuclear cells from AML patients harboring FLT3/ITD mutations were thawed, incubated overnight in culture medium, and centrifuged over Ficoll-Hypaque to eliminate dead cells (as described 34 ). Cells were then aliquoted into 96-well plates with increasing concentrations of AG1296. The MTT assay was performed at 72 h, with the results expressed as percent untreated control. In addition, cells were incubated for 4 h in the presence or absence of 10 M AG1296, then lysed and subject to immunoprecipitation with anti-FLT3 antibody. Immunoblotting (inset) was performed with anti-phosphotyrosine antibody, then the blot was stripped and re-probed with anti-FLT3 antibody.
phostin class, AG1296, as a potent inhibitor of FLT3 in murine Ba/F3 cells transfected with either the wild-type receptor or a constitutively activated TEL-FLT3 fusion. 33 This paper extends those studies to demonstrate that AG1296 also inhibits the kinase activity of FLT3/ITD mutations. The IC 50 of AG1296 towards FLT3 was found to be 0.3-0.5 M, similar to the values determined for inhibition of the PDGF and KIT receptors. 31, 32 This is similar to the potency of STI571 (Gleevec) towards BCR-ABL and KIT, which has been successfully employed to treat chronic myeloid leukemia (CML) and gastrointestinal stromal cell tumors (GISTs). [49] [50] [51] The mechanism of inhibition of FLT3 by AG1296 has not been studied but it is likely to result from competitive inhibition of ATP binding to the receptor which has been shown to be the mechanism by which AG1296 inhibits the closely related PDGF receptor.
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AG1296 inhibition of FLT3 results in growth arrest and apoptosis of Ba/F3 cells expressing FLT3/ITDs. These effects are probably the result of blocking the FLT3/ITD-mediated activation of many downstream signaling proteins. In this study these proteins are shown to include ERK 1 and 2, STAT 5A and B, VAV, CBL and SHP2. These results are in agreement with a previous report which demonstrated that FLT3/ITDs activated STAT 5 in 32D cells and that the transformation of these cells was at least partially dependent on this activation. 30 Interestingly, we found that both STAT 5A and STAT 5B were constitutively activated in our FLT3/ITD cell lines. A previous report indicated that STAT 5A, but not STAT 5B, was activated by wild-type FLT3 signaling. The activation of STAT 5B may be a feature unique to the FLT3/ITD mutant receptor, and may be responsible for some of the differences observed between Ba/F3 cells transfected with wild-type and constitutively activated FLT3. 9 Constitutive activation of STAT 5B has been associated with other malignancies 53, 54 and possibly contributes to the transforming effects of FLT3/ITD mutations. However, there are likely to be other proteins whose phosphorylation and activation is dependent on FLT3/ITD activation. Future studies will be required to more thoroughly define the entire pathways activated by FLT3/ITDs and how these pathways contribute to leukemogenesis.
Importantly, we found that AG1296 inhibits FLT3 autophosphorylation in primary AML samples harboring FLT3/ITD mutations. It also exerts a cytotoxic effect on these bone marrow cells in a manner similar to that which we observed using the related compound AG1295. 34 The growing evidence of an important role for FLT3 in leukemia suggests a potential for the use of FLT3 inhibitors to treat malignancies that are mediated by activated FLT3. This report demonstrates that a compound from the tyrphostin class selectively and potently inhibits the kinase activity and therefore the transforming potential of the most common type of FLT3 activating mutation found in AML. However, AG1296 also blocks the kinase activity of KIT and thus is more likely to have toxicity towards hematopoietic stem/progenitor cells than would a compound that would target only FLT3. The cell-based FLT3/ITD-transformed Ba/F3 proliferation assay can serve as a screening tool to identify and validate even more potent, specific inhibitors of FLT3/ITDs. This should lead to the development of FLT3 inhibitors with the appropriate bioavailability and pharmacokinetic parameters that will enable them to be used as specific therapy in AML patients expressing mutant FLT3.
